FDA 483 OBSERVATION · #224 OF 1,945 MOST-CITED
Valid stability test methods
FDA cited this observation 133 times across 126 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 5.2× the rate of the average FDA-cited firm (40.5% vs 7.8%), across 126 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
The written stability program for drug products does not include specific test methods.
The written stability program for drug products does not include meaningful test methods.
The written stability program for drug products does not include reliable, meaningful and specific test methods.
The written stability program for drug products does not include reliable, meaningful and specific test methods.
The written stability program for drug products does not include specific test methods.
The written stability program for drug products does not include specific test methods.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →